SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 2188699

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2188699

Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Type (IVD, LDT, Imaging), By Indication (Breast Cancer, Lung Cancer), By End-use, By Test Type By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 180 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Cancer Diagnostics Market Summary

The global cancer diagnostics market size was valued at USD 28.6 billion in 2025 and is projected to reach USD 31.2 billion in 2026 to USD 58.7 billion by 2033, at a CAGR of 9.5% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 40.5% in 2025. Market growth is driven by the increasing global cancer burden, expansion of population-based screening programs, rising demand for early and accurate diagnosis, and growing adoption of molecular diagnostics, next-generation sequencing, liquid biopsy, and advanced imaging technologies.

Global Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global cancer diagnostics market report on the basis of product, type, indication, test type, end use, and region.

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Instruments
    • Pathology-based Instruments
    • Slide Staining Systems
    • Tissue Processing Systems
    • Cell Processors
    • PCR Instruments
    • NGS Instruments
    • Microarrays
    • Other Pathology-based Instruments
    • Imaging Instruments
    • Others
  • Consumables
    • Antibodies
    • Kits & reagents
    • Probes
    • Others
  • Services
  • Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • IVD
    • By Type
    • Diagnosis
    • Early Detection
    • Therapy Selection
    • Monitoring
    • By Technology
    • Polymerase Chain Reaction (PCR)
    • In Situ Hybridization (ISH)
    • Immunohistochemistry (IHC)
    • Next-generation Sequencing (NGS)
    • Microarrays
    • Flow Cytometry
    • Immunoassays
    • Other IVD Testing Technologies
  • LDT
  • Imaging
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET)
    • Mammography
    • Ultrasound
    • Others
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others
  • End use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Laboratories
  • Others
  • Test Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Biopsy
    • Fine-needle Aspiration
    • Core Biopsy
    • Surgical Biopsy
    • Skin Biopsy /Punch Biopsy
    • Others
  • Others
  • Regional Outlook (Revenue, USD Million; 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Norway
    • Denmark
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Product Code: GVR-1-68038-213-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Type Segment
    • 1.2.3. Indication Segment
    • 1.2.4. Test type Segment
    • 1.2.5. End Use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Global Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence Of Cancer
      • 3.2.1.2. Technological Advancements
      • 3.2.1.3. Rising Initiatives Undertaken By Public And Private Organizations
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Cost Of Diagnostic Imaging
      • 3.2.2.2. Radiation Exposure Likely To Limit Usage Of Ct Scans
    • 3.2.3. Market opportunity analysis
  • 3.3. Global Cancer Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Global Cancer Diagnostics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Cancer Diagnostics Market: Product Movement Analysis
  • 4.3. Global Cancer Diagnostics Market Size & Trend Analysis by Product, 2021 to 2033 (USD Million)
  • 4.4. Instruments
    • 4.4.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Pathology Based instruments
      • 4.4.2.1. Slide Staining Systems
        • 4.4.2.1.1. Slide Staining Systems Market, 2021 - 2033 (USD Billion)
      • 4.4.2.2. Tissue Processing Systems
        • 4.4.2.2.1. Tissue Processing Systems Market, 2021 - 2033 (USD Billion)
      • 4.4.2.3. Cell Processors
        • 4.4.2.3.1. Cell Processors Systems Market, 2021 - 2033 (USD Billion)
      • 4.4.2.4. PCR Instruments
        • 4.4.2.4.1. PCR Instruments Market, 2021 - 2033 (USD Billion)
      • 4.4.2.5. NGS Instruments
        • 4.4.2.5.1. NGS Instruments Market, 2021 - 2033 (USD Billion)
      • 4.4.2.6. Microarrays
        • 4.4.2.6.1. Microarrays Market, 2021 - 2033 (USD Billion)
      • 4.4.2.7. Other Pathology-based Instruments
        • 4.4.2.7.1. Other Pathology-based Instruments Market, 2021 - 2033 (USD Billion)
    • 4.4.3. Imaging Instruments
    • 4.4.4. Others
  • 4.5. Consumables
    • 4.5.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.1.1. Antibodies
        • 4.5.1.1.1. Antibodies market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.1.2. Kits & reagents
        • 4.5.1.2.1. Kits & reagents market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.1.3. Probes
        • 4.5.1.3.1. Probes market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.5.1.4. Others
        • 4.5.1.4.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6. Services
    • 4.6.1. Services market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Cancer Diagnostics Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Cancer Diagnostics Market Type Movement Analysis
  • 5.3. Global Cancer Diagnostics Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. IVD
    • 5.4.1. IVD Market, 2021 - 2033 (USD Billion)
    • 5.4.2. IVD Market, By Type 2021 - 2033 (USD Billion)
      • 5.4.2.1. Diagnosis
        • 5.4.2.1.1. Diagnosis Market, 2021 - 2033 (USD Billion)
      • 5.4.2.2. Early Detection
        • 5.4.2.2.1. Early Detection Market, 2021 - 2033 (USD Billion)
      • 5.4.2.3. Therapy Selection
        • 5.4.2.3.1. Therapy Selection Market, 2021 - 2033 (USD Billion)
      • 5.4.2.4. Monitoring
        • 5.4.2.4.1. Monitoring Market, 2021 - 2033 (USD Billion)
    • 5.4.3. IVD Market, By Technology 2021 - 2033 (USD Billion)
      • 5.4.3.1. Polymerase Chain Reaction (PCR)
        • 5.4.3.1.1. Polymerase Chain Reaction (PCR) Market, 2021 - 2033 (USD Billion)
      • 5.4.3.2. In Situ Hybridization (ISH)
        • 5.4.3.2.1. In Situ Hybridization (ISH) Market, 2021 - 2033 (USD Billion)
      • 5.4.3.3. Immunohistochemistry (IHC)
        • 5.4.3.3.1. Immunohistochemistry (IHC) Market, 2021 - 2033 (USD Billion)
      • 5.4.3.4. Next-generation Sequencing (NGS)
        • 5.4.3.4.1. Next-generation Sequencing (NGS) Market, 2021 - 2033 (USD Billion)
      • 5.4.3.5. Microarrays
        • 5.4.3.5.1. Microarrays Market, 2021 - 2033 (USD Billion)
      • 5.4.3.6. Flow Cytometry
        • 5.4.3.6.1. Flow Cytometry Market, 2021 - 2033 (USD Billion)
      • 5.4.3.7. Immunoassays
        • 5.4.3.7.1. Immunoassays Market, 2021 - 2033 (USD Billion)
      • 5.4.3.8. Other IVD Testing Technologies
        • 5.4.3.8.1. Other IVD Testing Technologies Market, 2021 - 2033 (USD Billion)
  • 5.5. LDT
    • 5.5.1. LDT Market, 2021 - 2033 (USD Billion)
  • 5.6. Imaging
  • 5.7. Imaging Market, 2021 - 2033 (USD Billion)
    • 5.7.1. Magnetic Resonance Imaging (MRI)
      • 5.7.1.1. Magnetic Resonance Imaging (MRI) Market, 2021 - 2033 (USD Billion)
    • 5.7.2. Computed Tomography (CT)
      • 5.7.2.1. Computed Tomography (CT) Market, 2021 - 2033 (USD Billion)
    • 5.7.3. Positron Emission Tomography (PET)
      • 5.7.3.1. Positron Emission Tomography (PET) Market, 2021 - 2033 (USD Billion)
    • 5.7.4. Mammography
      • 5.7.4.1. Mammography Market, 2021 - 2033 (USD Billion)
    • 5.7.5. Ultrasound
      • 5.7.5.1. Ultrasound Market, 2021 - 2033 (USD Billion)
    • 5.7.6. Others
      • 5.7.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Global Cancer Diagnostics Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Cancer Diagnostics Market Indication Movement Analysis
    • 6.2.1. Global Cancer Diagnostics Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
    • 6.2.2. Breast Cancer
      • 6.2.2.1. Breast Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.3. Colorectal Cancer
      • 6.2.3.1. Colorectal Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.4. Cervical Cancer
      • 6.2.4.1. Cervical Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.5. Lung Cancer
      • 6.2.5.1. Lung Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.6. Prostate Cancer
      • 6.2.6.1. Prostate Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.7. Skin Cancer
      • 6.2.7.1. Skin Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.8. Blood Cancer
      • 6.2.8.1. Blood Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.9. Kidney Cancer
      • 6.2.9.1. Kidney Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.10. Liver Cancer
      • 6.2.10.1. Liver Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.11. Pancreatic Cancer
      • 6.2.11.1. Pancreatic Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.12. Ovarian Cancer
      • 6.2.12.1. Ovarian Cancer Market, 2021 - 2033 (USD Billion)
    • 6.2.13. Othes
      • 6.2.13.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. Global Cancer Diagnostics Market: Test Type Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Cancer Diagnostics Market Test Type Movement Analysis
    • 7.2.1. Global Cancer Diagnostics Market Size & Trend Analysis, by Test Type, 2021 to 2033 (USD Million)
  • 7.3. Biopsy
    • 7.3.1. Biopsy market estimates and forecasts 2021 to 2033 (USD Million)
      • 7.3.1.1. Fine-needle Aspiration
        • 7.3.1.1.1. Fine-needle Aspiration market estimates and forecasts 2021 to 2033 (USD Million)
      • 7.3.1.2. Core Biopsy
        • 7.3.1.2.1. Core Biopsy market estimates and forecasts 2021 to 2033 (USD Million)
      • 7.3.1.3. Surgical Biopsy
        • 7.3.1.3.1. Surgical Biopsy market estimates and forecasts 2021 to 2033 (USD Million)
      • 7.3.1.4. Skin Biopsy /Punch Biopsy
        • 7.3.1.4.1. Skin Biopsy /Punch Biopsy market estimates and forecasts 2021 to 2033 (USD Million)
      • 7.3.1.5. Others
        • 7.3.1.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4. Other
    • 7.4.1. Other market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Global Cancer Diagnostics Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Cancer Diagnostics Market End Use Movement Analysis
    • 8.2.1. Global Cancer Diagnostics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 8.3. Hospitals
    • 8.3.1. Hospitals market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4. Laboratories
    • 8.4.1. Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Others
    • 8.5.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Cancer Diagnostics Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Dashboard
  • 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 9.3. North America
    • 9.3.1. U.S.
      • 9.3.1.1. Key country dynamics
      • 9.3.1.2. Regulatory framework/ reimbursement structure
      • 9.3.1.3. Competitive scenario
      • 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.2. Canada
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework/ reimbursement structure
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.3.3. Mexico
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework/ reimbursement structure
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4. Europe
    • 9.4.1. UK
      • 9.4.1.1. Key country dynamics
      • 9.4.1.2. Regulatory framework/ reimbursement structure
      • 9.4.1.3. Competitive scenario
      • 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework/ reimbursement structure
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.3. France
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework/ reimbursement structure
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.4. Italy
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework/ reimbursement structure
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.5. Spain
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework/ reimbursement structure
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.6. Norway
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework/ reimbursement structure
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.7. Sweden
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework/ reimbursement structure
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.4.8. Denmark
      • 9.4.8.1. Key country dynamics
      • 9.4.8.2. Regulatory framework/ reimbursement structure
      • 9.4.8.3. Competitive scenario
      • 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Japan
      • 9.5.1.1. Key country dynamics
      • 9.5.1.2. Regulatory framework/ reimbursement structure
      • 9.5.1.3. Competitive scenario
      • 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.2. China
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework/ reimbursement structure
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.3. India
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework/ reimbursement structure
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.4. Australia
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework/ reimbursement structure
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Regulatory framework/ reimbursement structure
      • 9.5.5.3. Competitive scenario
      • 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Regulatory framework/ reimbursement structure
      • 9.5.6.3. Competitive scenario
      • 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Brazil
      • 9.6.1.1. Key country dynamics
      • 9.6.1.2. Regulatory framework/ reimbursement structure
      • 9.6.1.3. Competitive scenario
      • 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.6.2. Argentina
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/ reimbursement structure
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7. MEA
    • 9.7.1. South Africa
      • 9.7.1.1. Key country dynamics
      • 9.7.1.2. Regulatory framework/ reimbursement structure
      • 9.7.1.3. Competitive scenario
      • 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/ reimbursement structure
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.3. UAE
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/ reimbursement structure
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 9.7.4. Kuwait
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/ reimbursement structure
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company/Competition Categorization
  • 10.2. Strategy Mapping
  • 10.3. Company Market Share Analysis, 2025
  • 10.4. List of Key Certification Providers/Scheme Owners
  • 10.5. Company Profiles/Listing
    • 10.5.1. Abbott
      • 10.5.1.1. Company overview
      • 10.5.1.2. Financial performance
      • 10.5.1.3. Technology benchmarking
      • 10.5.1.4. Strategic initiatives
    • 10.5.2. F. Hoffmann-La Roche Ltd
      • 10.5.2.1. Company overview
      • 10.5.2.2. Financial performance
      • 10.5.2.3. Product benchmarking
      • 10.5.2.4. Strategic initiatives
    • 10.5.3. GE Healthcare
      • 10.5.3.1. Company overview
      • 10.5.3.2. Financial performance
      • 10.5.3.3. Product benchmarking
      • 10.5.3.4. Strategic initiatives
    • 10.5.4. QIAGEN
      • 10.5.4.1. Company overview
      • 10.5.4.2. Financial performance
      • 10.5.4.3. Product benchmarking
      • 10.5.4.4. Strategic initiatives
    • 10.5.5. BD
      • 10.5.5.1. Company overview
      • 10.5.5.2. Financial performance
      • 10.5.5.3. Product benchmarking
      • 10.5.5.4. Strategic initiatives
    • 10.5.6. Koninklijke Philips N.V. (Philips)
      • 10.5.6.1. Company overview
      • 10.5.6.2. Financial performance
      • 10.5.6.3. Product benchmarking
      • 10.5.6.4. Strategic initiatives
    • 10.5.7. Siemens Healthcare GmbH
      • 10.5.7.1. Company overview
      • 10.5.7.2. Financial performance
      • 10.5.7.3. Product benchmarking
      • 10.5.7.4. Strategic initiatives
    • 10.5.8. Hologic, Inc.
      • 10.5.8.1. Company overview
      • 10.5.8.2. Financial performance
      • 10.5.8.3. Product benchmarking
      • 10.5.8.4. Strategic initiatives
    • 10.5.9. Thermo Fisher Scientific, Inc.
      • 10.5.9.1. Company overview
      • 10.5.9.2. Financial performance
      • 10.5.9.3. Product benchmarking
      • 10.5.9.4. Strategic initiatives
    • 10.5.10. Illumina, Inc.
      • 10.5.10.1. Company overview
      • 10.5.10.2. Financial performance
      • 10.5.10.3. Product benchmarking
      • 10.5.10.4. Strategic initiatives
Product Code: GVR-1-68038-213-6

List of Tables

  • Table 1. Global cancer diagnostics market, by region, 2021 - 2033 (USD Billion)
  • Table 2. Global cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 3. Global cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 4. Global cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 5. Global cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 6. Global cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 7. North America cancer diagnostics market, by country, 2021 - 2033 (USD Billion)
  • Table 8. North America cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 9. North America cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 10. North America cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 11. North America cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 12. North America cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 13. U.S. cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 14. U.S. cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 15. U.S. cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 16. U.S. cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 17. U.S. cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 18. Canada cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 19. Canada cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 20. Canada cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 21. Canada cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 22. Canada cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 23. Europe cancer diagnostics market, by country, 2021 - 2033 (USD Billion)
  • Table 24. Europe cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 25. Europe cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 26. Europe cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 27. Europe cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 28. Europe cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 29. UK cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 30. UK cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 31. UK cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 32. UK cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 33. UK cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 34. Germany cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 35. Germany cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 36. Germany cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 37. Germany cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 38. Germany cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 39. France cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 40. France cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 41. France cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 42. France cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 43. France cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 44. Italy cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 45. Italy cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 46. Italy cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 47. Italy cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 48. Italy cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 49. Spain cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 50. Spain cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 51. Spain cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 52. Spain cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 53. Spain cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 54. Denmark cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 55. Denmark cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 56. Denmark cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 57. Denmark cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 58. Denmark cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 59. Sweden cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 60. Sweden cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 61. Sweden cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 62. Sweden cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 63. Sweden cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 64. Norway cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 65. Norway cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 66. Norway cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 67. Norway cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 68. Norway cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 69. Asia Pacific cancer diagnostics market, by country, 2021 - 2033 (USD Billion)
  • Table 70. Asia Pacific cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 71. Asia Pacific cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 72. Asia Pacific cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 73. Asia Pacific cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 74. Asia Pacific cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 75. Japan cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 76. Japan cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 77. Japan cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 78. Japan cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 79. Japan cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 80. China cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 81. China cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 82. China cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 83. China cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 84. China cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 85. India cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 86. India cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 87. India cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 88. India cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 89. India cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 90. South Korea cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 91. South Korea cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 92. South Korea cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 93. South Korea cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 94. South Korea cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 95. Thailand cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 96. Thailand cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 97. Thailand cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 98. Thailand cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 99. Thailand cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 100. Australia cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 101. Australia cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 102. Australia cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 103. Australia cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 104. Australia cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 105. Latin America cancer diagnostics market, by country, 2021 - 2033 (USD Billion)
  • Table 106. Latin America cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 107. Latin America cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 108. Latin America cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 109. Latin America cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 110. Latin America cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 111. Brazil cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 112. Brazil cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 113. Brazil cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 114. Brazil cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 115. Brazil cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 116. Mexico cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 117. Mexico cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 118. Mexico cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 119. Mexico cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 120. Mexico cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 121. Argentina cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 122. Argentina cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 123. Argentina cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 124. Argentina cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 125. Argentina cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 126. Middle East & Africa cancer diagnostics market, by country, 2021 - 2033 (USD Billion)
  • Table 127. Middle East & Africa cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 128. Middle East & Africa cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 129. Middle East & Africa cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 130. Middle East & Africa cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 131. Middle East & Africa cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 132. South Africa cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 133. South Africa cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 134. South Africa cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 135. South Africa cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 136. South Africa cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 137. Saudi Arabia cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 138. Saudi Arabia cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 139. Saudi Arabia cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 140. Saudi Arabia cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 141. Saudi Arabia cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 142. UAE cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 143. UAE cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 144. UAE cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 145. UAE cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 146. UAE cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)
  • Table 147. Kuwait cancer diagnostics market, by product, 2021 - 2033 (USD Billion)
  • Table 148. Kuwait cancer diagnostics market, by type, 2021 - 2033 (USD Billion)
  • Table 149. Kuwait cancer diagnostics market, by Indication, 2021 - 2033 (USD Billion)
  • Table 150. Kuwait cancer diagnostics market, by end use, 2021 - 2033 (USD Billion)
  • Table 151. Kuwait cancer diagnostics market, by test type, 2021 - 2033 (USD Billion)

List of Figures

  • Fig 1. Cancer diagnostics market segmentation
  • Fig 2. Market research process
  • Fig 3. Information procurement
  • Fig 4. Primary research pattern
  • Fig 5. Market research approaches
  • Fig 6. Value chain based sizing & forecasting
  • Fig 7. QFD modelling for market share assessment
  • Fig 8. Market formulation & validation
  • Fig 9. Market snapshot
  • Fig 10. Product and type segment snapshot
  • Fig 11. Indication segment snapshot
  • Fig 12. End use and test type segment snapshot
  • Fig 13. Competitive landscape snapshot
  • Fig 14. Cancer diagnostics market value, 2025 (USD Billion)
  • Fig 15. Market dynamics
  • Fig 16. Incidence of most common cancers globally, 2025
  • Fig 17. Porter's five forces analysis
  • Fig 18. PESTLE analysis
  • Fig 19. Cancer diagnostics market: Product outlook and key takeaways
  • Fig 20. Cancer diagnostics market: Product movement analysis
  • Fig 21. Instruments market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 22. Pathology-based instruments market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 23. Slide staining systems market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 24. Tissue processing systems market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 25. Cell processors market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 26. PCR instruments market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 27. NGS instruments market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 28. Microarrays market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 29. Other pathology-based instruments market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 30. Imaging instruments market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 31. Others market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 32. Consumables market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 33. Antibodies market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 34. Kits & reagents market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 35. Probes market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 36. Others market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 37. Services market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 38. Cancer diagnostics market: Type outlook and key takeaways
  • Fig 39. Cancer diagnostics market: Type movement analysis
  • Fig 40. IVD market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 41. Diagnosis market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 42. Early detection market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 43. Therapy selection market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 44. Monitoring market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 45. Polymerase Chain Reaction (PCR) market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 46. In Situ Hybridization (ISH) market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 47. Immunohistochemistry (IHC) market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 48. Next-generation Sequencing (NGS) market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 49. Microarrays market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 50. Flow cytometry market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 51. Immunoassays market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 52. Other IVD testing technologies market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 53. LDT market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 54. Imaging market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 55. Magnetic Resonance Imaging (MRI) market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 56. Computed Tomography (CT) market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 57. Positron Emission Tomography (PET) market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 58. Mammography market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 59. Ultrasound market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 60. Others market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 61. Cancer diagnostics market: Indication outlook and key takeaways
  • Fig 62. Cancer diagnostics market: Indication movement analysis
  • Fig 63. Breast cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 64. Colorectal cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 65. Cervical cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 66. Lung cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 67. Prostate cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 68. Skin cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 69. Blood cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 70. Kidney cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 71. Liver cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 72. Pancreatic cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 73. Ovarian cancer market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 74. Others market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 75. Cancer diagnostics market: End use outlook and key takeaways
  • Fig 76. Cancer diagnostics market: End use movement analysis
  • Fig 77. Hospitals market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 78. Laboratories market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 79. Others market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 80. Cancer diagnostics market: Test type outlook and key takeaways
  • Fig 81. Cancer diagnostics market: Test type movement analysis
  • Fig 82. Biopsy market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 83. Fine-needle aspiration market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 84. Core biopsy market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 85. Surgical biopsy market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 86. Skin biopsy/punch biopsy market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 87. Others market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 88. Others market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 89. Cancer Diagnostics Market revenue, by region, 2025 & 2030 (USD Billion)
  • Fig 90. Regional marketplace: Key takeaways
  • Fig 91. Regional marketplace: Key takeaways
  • Fig 92. North America cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 93. Key country dynamics
  • Fig 94. U.S. cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 95. Cancer incidence, 2021 - 2033
  • Fig 96. Key country dynamics
  • Fig 97. Canada cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 98. Cancer incidence, 2021 - 2033
  • Fig 99. Europe cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 100. Key country dynamics
  • Fig 101. UK cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 102. Cancer incidence, 2021 - 2033
  • Fig 103. Key country dynamics
  • Fig 104. Germany cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 105. Cancer incidence, 2021 - 2033
  • Fig 106. Key country dynamics
  • Fig 107. France cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 108. Cancer incidence, 2021 - 2033
  • Fig 109. Key country dynamics
  • Fig 110. Spain cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 111. Cancer incidence, 2021 - 2033
  • Fig 112. Key country dynamics
  • Fig 113. Italy cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 114. Cancer incidence, 2021 - 2033
  • Fig 115. Key country dynamics
  • Fig 116. Denmark cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 117. Target disease prevalence
  • Fig 118. Key country dynamics
  • Fig 119. Sweden cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 120. Five most common cancers in Sweden
  • Fig 121. Key country dynamics
  • Fig 122. Norway cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 123. Number of new cancer cases in 2020, both sexes, all ages
  • Fig 124. Rest of Europe cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 125. Asia Pacific cancer diagnostics market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 126. Key country dynamics
  • Fig 127. Japan cancer diagnostics market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 128. Cancer incidence, 2021 to 2033
  • Fig 129. Key country dynamics
  • Fig 130. China cancer diagnostics market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 131. Cancer incidence, 2021 to 2033
  • Fig 132. China regulatory details
  • Fig 133. Key country dynamics
  • Fig 134. India cancer diagnostics market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 135. Cancer incidence, 2021 to 2033
  • Fig 136. Key country dynamics
  • Fig 137. Australia cancer diagnostics market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 138. Cancer incidence, 2021 to 2033
  • Fig 139. Key country dynamics
  • Fig 140. Thailand cancer diagnostics market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 141. Cancer incidence, 2021 to 2033
  • Fig 142. Key country dynamics
  • Fig 143. South Korea cancer diagnostics market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 144. Cancer incidence 2021 to 2033
  • Fig 145. South Korean regulations in four hierarchical orders
  • Fig 146. South Korea reimbursement scenario
  • Fig 147. Rest of Asia Pacific cancer diagnostics market estimates and forecast, 2021 - 2033 (USD Billion)
  • Fig 148. Latin America cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 149. Key country dynamics
  • Fig 150. Brazil cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 151. Estimated number of new cancer cases in Brazil
  • Fig 152. Key country dynamics
  • Fig 153. Mexico cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 154. Estimated number of new cancer cases in Mexico
  • Fig 155. Key country dynamics
  • Fig 156. Argentina cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 157. Estimated number of new cancer cases in Argentina
  • Fig 158. Rest of Latin America cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 159. MEA cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 160. Key country dynamics
  • Fig 161. South Africa cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 162. Cancer prevalence-2021 - 2033
  • Fig 163. Key country dynamics
  • Fig 164. Saudi Arabia cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 165. Cancer prevalence-2021 - 2033
  • Fig 166. Key country dynamics
  • Fig 167. UAE cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig 168. Cancer prevalence 2021 - 2033
  • Fig 169. Key country dynamics
  • Fig 170. Kuwait cancer diagnostics market estimates and forecasts, 2021 - 2033 (USD Billion)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!